<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481845</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-08051</org_study_id>
    <secondary_id>BRSADJ0008</secondary_id>
    <secondary_id>97923</secondary_id>
    <nct_id>NCT00481845</nct_id>
  </id_info>
  <brief_title>Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer</brief_title>
  <official_title>Randomized Phase 2 Trial of Anastrozole Combined With Novel Agent ZD6474 in the Neoadjuvant Treatment of Postmenopausal Patients With Hormone Receptor-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we plan to study the combination of ZD6474, a dual inhibitor of EGFR and
      VEGFR-2 with anastrozole in the neoadjuvant setting for patients with Stage I-III breast
      cancer. The aim is to overcome mechanisms of resistance and simultaneously block multiple
      critical signaling pathways known to stimulate breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of adjuvant chemotherapy and endocrine therapy has had a significant impact on breast
      cancer survival. However, not all patients will benefit from each of these therapies.
      Increasing data suggests that patients with hormone receptor-positive breast cancer derive
      marginal benefit from the addition of adjuvant chemotherapy. Identification and
      characterization of cellular signaling pathways active in the pathogenesis of breast cancer
      has lead to the development of multiple targeted therapies that hold enormous promise for
      patients with less toxicity than conventional chemotherapy. Treatment strategies employing
      neoadjuvant therapy have found that pCR is predictive for ultimate outcome. Due to this, the
      use of neoadjuvant therapy has become an intense area of investigation in operable breast
      cancer. In the IMPACT trial, the aromatase inhibitor anastrozole was found to improve
      eligibility for breast conservation and was associated with a favorable clinical objective
      response after 12 weeks of therapy.

      In this proposed study, we plan to study the combination of ZD6474, a dual inhibitor of EGFR
      and VEGFR-2, with anastrozole in the neoadjuvant setting for patients with Stage I-III breast
      cancer. The aim is to overcome mechanisms of resistance and simultaneously block multiple
      critical signaling pathways known to stimulate breast cancer. The two agents have
      non-overlapping toxicities and are both administered orally, allowing for a more tolerable
      treatment regimen. By using this combination in the neoadjuvant setting, we will target the
      critical signaling pathways early and follow tumor responses during therapy, allowing for
      prompt evaluation of the effectiveness of this treatment strategy. Pathologic tumor specimens
      obtained at the time of definitive surgery will be evaluated for pathologic complete response
      thus adding to the body of literature. By examining molecular markers such as ER, PR, EGFR,
      and Ki-67 pre- and post-treatment, we hope to correlate modulations in these biomarkers to
      response. Finally, using a novel second generation functional breast MRI we will investigate
      the ability of MRI to predict response to antiangiogenic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Objective Response by MRI</measure>
    <time_frame>1 year</time_frame>
    <description>Determine tumor objective response rate by MRI. (CR): Disappearance of the target lesion (PR): At least a 30% decrease in the longest diameter of the target lesion taking as reference the baseline LD (PD): At least a 20% increase in the LD of target lesion, taking as reference the baseline LD or the appearance of one or more new lesions (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the baseline LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vandetanib + Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vandetanib and Anastrozole as neoadjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole as neoadjuvant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>300 mg daily</description>
    <arm_group_label>Vandetanib + Anastrozole</arm_group_label>
    <other_name>Zactima</other_name>
    <other_name>ZD6474</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1 mg daily</description>
    <arm_group_label>Vandetanib + Anastrozole</arm_group_label>
    <arm_group_label>Anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically confirmed invasive, hormone receptor-positive (ER and/or PR positive) breast
        cancer

          -  Stage I-III breast cancer including any primary tumor ≥ 1 cm by ultrasound

          -  Diagnosis by core needle biopsy with placement of metallic clip at tumor site

          -  Sentinel lymph node biopsy (US-guided FNA may be substituted if palpable axillary
             lymphadenopathy)

          -  Evaluation by a surgeon to determine eligibility for breast conservation

          -  Postmenopausal status (age ≥ 60 yo; or &lt; 60 yo and FSH and estradiol in the
             postmenopausal range, prior bilateral oophorectomy)

          -  Serum creatinine &lt; 1.5 x upper limit of normal (ULN) or creatinine clearance &gt; 50
             mL/minute (calculated by Cockcroft-Gault formula.)

          -  Serum bilirubin &lt; 1.5 x ULN

          -  Serum potassium ≥ 4 mmol/L (supplementation allowed)

          -  Serum calcium or magnesium within normal range (supplementation allowed)

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 x ULN or
             alkaline phosphatase (ALP) ≤ 2.5 x ULN

          -  ECOG Performance Status 0,1,2

          -  ECG QTc &lt; 480 msec

          -  Measurable disease

          -  Written, informed consent

        Exclusion Criteria:- Inflammatory breast cancer

          -  Metastatic breast cancer excluding disease in regional lymph nodes

          -  Inoperable disease considered irreversible with neoadjuvant endocrine therapy

          -  HER2-overexpressed breast cancer

          -  Prior chemotherapy or radiotherapy for the treatment of the current breast cancer

          -  Prior hormonal therapy for the treatment of the current breast cancer

          -  Prior surgical biopsy, lumpectomy, mastectomy for the current breast cancer

          -  Any concurrent condition which in the Investigator's opinion makes it inappropriate
             for the patient to participate in the trial or which would jeopardize compliance with
             the protocol

          -  Currently active diarrhea that may affect the ability of the patient to absorb ZD6474
             or tolerate diarrhea

          -  Clinically significant cardiac event such as myocardial infarction; New York Heart
             Association (NYHA) classification of heart disease &gt;2 within 3 months before entry; or
             presence of cardiac disease that, in the opinion of the Investigator, increases the
             risk of ventricular arrhythmia.

          -  History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy,
             trigeminy, ventricular tachycardia (VT) or uncontrolled atrial fibrillation) which is
             symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained VT. Atrial
             fibrillation controlled on medication is not excluded.

          -  Previous history of QTc prolongation as a result of another medication that required
             discontinuation of that medication.

          -  Congenital long QT syndrome or 1st degree relative with unexplained sudden death &lt; 40
             years of age.

          -  Presence of left bundle branch block (LBBB).

          -  QTc with Bazett's correction that is unmeasurable, or ≥ 480 msec on screening ECG. If
             a patient has QTc ≥ 480 msec on screening ECG, the screen ECG may be repeated twice
             (at least 24 hours apart). The average QTc from the three screening ECGs must be &lt; 480
             msec in order for the patient to be eligible for the study.

          -  Use of any concomitant medication that may cause QTc prolongation, induce Torsades de
             Pointes or induce CYP3A4 function.

          -  Hypertension not controlled by medical therapy (systolic blood pressure greater than
             160 mm Hg or diastolic blood pressure greater than 100 mm hg).

          -  Previous or current malignancies of other histologies within the last 5 years, with
             the exception of cervical carcinoma in situ and adequately treated basal cell or
             squamous cell carcinoma of the skin.

          -  Major surgery within 4 weeks or incompletely healed surgical incision before starting
             study therapy.

          -  Receipt of any investigational agents within 30 days prior to commencing study
             treatment

          -  Previous enrollment or randomization of treatment in the present study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D Pegram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Cancer Institute, Stanford University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <results_first_submitted>December 13, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2017</results_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mark Pegram</investigator_full_name>
    <investigator_title>Susy Yuan-Huey Hung Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vandetanib + Anastrozole</title>
          <description>Vandetanib and Anastrozole as neoadjuvant therapy</description>
        </group>
        <group group_id="P2">
          <title>Anastrozole</title>
          <description>Anastrozole as neoadjuvant therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vandetanib + Anastrozole</title>
          <description>Vandetanib and Anastrozole as neoadjuvant therapy</description>
        </group>
        <group group_id="B2">
          <title>Anastrozole</title>
          <description>Anastrozole as neoadjuvant therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tumor Objective Response by MRI</title>
        <description>Determine tumor objective response rate by MRI. (CR): Disappearance of the target lesion (PR): At least a 30% decrease in the longest diameter of the target lesion taking as reference the baseline LD (PD): At least a 20% increase in the LD of target lesion, taking as reference the baseline LD or the appearance of one or more new lesions (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the baseline LD.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib + Anastrozole</title>
            <description>Vandetanib and Anastrozole as neoadjuvant therapy</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole as neoadjuvant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Objective Response by MRI</title>
          <description>Determine tumor objective response rate by MRI. (CR): Disappearance of the target lesion (PR): At least a 30% decrease in the longest diameter of the target lesion taking as reference the baseline LD (PD): At least a 20% increase in the LD of target lesion, taking as reference the baseline LD or the appearance of one or more new lesions (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the baseline LD.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response- CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response- PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease- PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease-SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Complete Response</title>
        <time_frame>1 year</time_frame>
        <population>CR+PR</population>
        <group_list>
          <group group_id="O1">
            <title>Vandetanib + Anastrozole</title>
            <description>Vandetanib and Anastrozole as neoadjuvant therapy</description>
          </group>
          <group group_id="O2">
            <title>Anastrozole</title>
            <description>Anastrozole as neoadjuvant therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response</title>
          <population>CR+PR</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>All AEs or SAEs collected during the 4 months (12 cycles) span on treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Vandetanib + Anastrozole</title>
          <description>Vandetanib and Anastrozole as neoadjuvant therapy</description>
        </group>
        <group group_id="E2">
          <title>Anastrozole</title>
          <description>Anastrozole as neoadjuvant therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Vague chest discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>increasing reflux symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>esophageal spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sweaty palms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Painic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Onset asthma symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Daniel Pegram; Susy Yuan-Huey Hung Professor</name_or_title>
      <organization>Stanford Cancer Institute, Stanford University</organization>
      <phone>650-723-5801</phone>
      <email>mpegram@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

